Brivanib

DB11958InvestigationalSmall molecule

Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor and Fibroblast growth factor receptor
Curator reviewed
Formula / weight: C₁₉H₁₉FN₄O₃ · 370.384 g/mol (avg)
Code names: BMS-540215

Resolves to

Compound

UNIIDDU33B674ICAS649735-46-6ChEMBLCHEMBL377300ChEBI94562PubChem11234052

Structure

InChIKeyWCWUXEGQKLTGDX-LLVKDONJSA-NSMILESC[C@@H](O)COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C

Targets

P35968KDR

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brivanib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account